Cornerstone Planning Group’s Vir Biotechnology VIR Stock Holding History

Cornerstone Planning Group’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$935	Hold	100	–	–	﹤0.01%	1526
2026 Q1	$1K	Hold	100	–	–	﹤0.01%	1462
2025 Q4	$757	Buy	100 +87	+669%	+$518	﹤0.01%	1407
2025 Q3	$450	Sell	13 -87	-87%	-$445	﹤0.01%	1505
2025 Q2	$511	Hold	100	–	–	﹤0.01%	1295
2025 Q1	$597	Hold	100	–	–	﹤0.01%	1250
2024 Q4	$1.03K	Hold	100	–	–	﹤0.01%	946
2024 Q3	$761	Hold	100	–	–	﹤0.01%	1002
2024 Q2	$865	Hold	100	–	–	﹤0.01%	973
2024 Q1	$1.04K	Hold	100	–	–	﹤0.01%	779
2023 Q4	$1.01K	Hold	100	–	–	﹤0.01%	715
2023 Q3	$937	Hold	100	–	–	﹤0.01%	799
2023 Q2	$2.45K	Buy	+100	New	+$2.51K	﹤0.01%	1099
2022 Q4	$2.69K	Buy	+100	New	+$2.45K	﹤0.01%	1113

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Cornerstone Planning Group's VIR Position: Q2 2026 in Review

Cornerstone Planning Group held its Vir Biotechnology (VIR) position steady in Q2 2026 at 100 shares worth $935. The position accounts for ﹤0.01% of the portfolio, ranked #1526.

Cornerstone Planning Group first reported a position in VIR in Q4 2022 and has held it in 14 quarters since. The position peaked at $2.69K in Q4 2022. 238 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Cornerstone Planning Group held 100 shares of Vir Biotechnology worth $935 as of Q2 2026.
Cornerstone Planning Group left its Vir Biotechnology share count unchanged in Q2 2026.
Vir Biotechnology made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q2 2026, its #1526 holding.
Cornerstone Planning Group first reported a position in Vir Biotechnology in Q4 2022 and has held it in 14 quarters since.
Cornerstone Planning Group's Vir Biotechnology position peaked at $2.69K in Q4 2022.
238 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.